XXXX in @entity1 treated for @entity5 .

@entity1 @entity5 @entity281 @entity1398 @entity364 @entity4005
UNASSIGNED: @entity1398 ( @entity1398 ) in @entity1 treated for @entity5 is a common and direct sequela of chemotherapy. Episodes of @entity1398 can be life-threatening, and demand prompt recognition, assessment and treatment with broad spectrum antibiotics. While in the majority of episodes no @entity281 is identified, 10-20% are secondary to a @entity281 ( @entity281 ). A reduction in episodes of @entity281 could be achieved through robust infection prevention strategies, such as CVL care bundles. Alongside good antimicrobial stewardship, these strategies could reduce the risk of emergent, multi-drug resistant (MDR) @entity281 . Emerging bacterial pathogens in @entity281 include Viridans Group Streptococci (VGS) and Enterobacteriaceae such as @entity4005 spp. which are known for their ability to carry MDR genes. There is also increased recognition of the role of invasive @entity364 (IFI) in @entity1398 , in particular with Aspergillus spp. Novel diagnostics, including multiplex blood and respiratory polymerase chain reaction assays can identify @entity281 early in @entity1398 , facilitating targeted therapy, and reducing unnecessary antimicrobial exposure. Given appropriate, and sensitive rapid diagnostics, potential also exists to safely inform the risk assessment of @entity1 with @entity1398 , identifying those at low risk of complication, who could be treated in the out- @entity1 setting. Several clinical decision rules (CDR) have now been developed and validated in defined populations, for the risk assessment of @entity1 being treated for @entity5 . Future research is needed to develop a universal CDR to improve the management of @entity1 with @entity1398 .
